Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant
- 29 February 2020
- journal article
- research article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 258 (5) , 1023-1030
Abstract
Purpose To determine the time to disease recurrence with long-acting injectable fluocinolone acetonide implant (FAi) for noninfectious intermediate, posterior, and panuveitis. Methods This was a retrospective study of patients with at least 12 months of follow-up who had completed a 2-year prospective, investigational new drug study with 0.18-mg FAi. Time to uveitis recurrence or cystoid macular edema (CME) occurrence was recorded. Results Twelve eyes from 12 participants (mean age 43 years, range 25–64 years) were included. Patients were followed for a mean of 34.2 months (range, 12.0–56.9 months) after completion of the prospective trial. Five eyes (42%) did not have a documented uveitis recurrence or CME occurrence. Five eyes (42%) had a uveitis recurrence with the mean time to recurrence 36.1 months (range, 22.8–61.1 months) after FAi implantation. Two eyes (16%) had CME alone, the mean time to occurrence 36.9 months (range 36.1–42.1 months). On Kaplan-Meier analysis, the estimated probability of remaining recurrence-free 36 months after FAi implantation was 0.67 (95% confidence interval, 0.34–0.86). Conclusions Data of study participants after completing a clinical trial suggest that the injectable FAi for noninfectious uveitis can provide control for 3 years on average. These long-term data support the use of FAi to control noninfectious uveitis.Keywords
Funding Information
- Heed Ophthalmic Foundation (2018-2019)
- Research to Prevent Blindness (2018 Unrestricted Grant from Research to Duke Eye Center)
- National Eye Institute (Duke Eye Center P30 Core Grant)
This publication has 11 references indexed in Scilit:
- Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior SegmentOphthalmology, 2019
- Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and PanuveitisOphthalmology, 2016
- Periocular Corticosteroid Injections in UveitisOphthalmology, 2014
- Randomized Comparison of Systemic Anti-inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment TrialOphthalmology, 2011
- Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior UveitisArchives of Ophthalmology (1950), 2011
- Fluocinolone Acetonide Implant (Retisert) for Noninfectious Posterior UveitisOphthalmology, 2006
- Outcome of Intravitreal Triamcinolone in UveitisOphthalmology, 2005
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panelAmerican Journal of Ophthalmology, 2000
- Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior UveitisOphthalmology, 1985